Subscribe
Close
  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Renew

Alora Pharmaceuticals Relocates Two Business Headquarters to Alpharetta, Georgia

03/01/2018
Alora Pharmaceuticals, parent company of Avion Pharmaceuticals, and Acella Pharmaceuticals, relocated the corporate headquarters of its two companies to a new 58,000 sq. ft. facility at 1880 McFarland Parkway in Alpharetta, Georgia.

The new headquarters will provide increased office space, climate-controlled warehouse space for 1,000 pallet locations, as well as Current Good Manufacturing Process compliant capabilities with monitored security. The new state-of-the-art facility also will include a world-class training area and conference capabilities. According to company leadership, the new headquarters will help accommodate the projected growth planned for both companies in the coming years.

"This move has been long overdue, as we have been searching for the ideal space that provides everything we need for our continued growth, from warehousing to state-of-the-art office space," stated Alora CEO Art Deas. "As we continue to expand our product portfolio, develop new services and add new staff, we will have the space to support this growth."

Avion Pharmaceuticals, LLC is a specialty pharmaceutical company formed to develop and market a portfolio of innovative pharmaceutical products in the Women's Heath therapeutic category. Avion Pharmaceuticals focuses on identifying opportunities to acquire and enhance the market potential of innovative, commercially available therapeutics and late-stage development drugs to fulfill unmet medical needs.

Acella develops markets, sells and distributes a broad portfolio of non-branded pharmaceutical and other products in the areas of Dermatology, Women's Health, Pediatrics and other applications. Acella specializes in identifying and bringing to market quality, affordable products to customers and patients.

Article Discussion

Share